Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine

It’s been a tough year of layoffs and pipeline culls for Praxis Precision Medicines, but the biotech is ending 2022 on a positive note courtesy of a collaboration with UCB to develop a potential first-ever treatment for a specific type of epilepsy.